High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor κB and AP-1 activities

Journal of Endocrinology

Volumn 196, Issue 1, 2008, Pages 45-55

  Nareika, Alena ^a   Im, Yeong Bin ^a   Game, Bryan A ^a   Slate, Elizabeth H ^b   Sanders, John J ^b   London, Steven D ^b   Lopes Virella, Maria F ^a   Huang, Yan ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR AP 1; CURCUMIN; DNA; MESSENGER RNA;

ARTICLE; CELL LEVEL; CELL STRAIN U937; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOASSAY; MOLECULAR MECHANICS; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; CELL MEMBRANE; CHEMISTRY; CULTURE MEDIUM; CYTOPLASM; DRUG EFFECT; GENETICS; HISTIOCYTE; METABOLISM; MONOCYTE; UPREGULATION;

ANTIGENS, CD14; CELL MEMBRANE; CULTURE MEDIA, CONDITIONED; CURCUMIN; CYTOPLASM; DNA; GLUCOSE; HISTIOCYTES; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 1; MONOCYTES; NF-KAPPA B; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; U937 CELLS; UP-REGULATION;

EID: 38849112070     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-07-0145     Document Type: Article

References (39)

1. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE & Price JE 2005 Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clinical Cancer Research 11 7490-7498.
2. Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A & Dandona P 2004 Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. American Journal of Clinical Nutrition 80 51-57.
3. Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, Chaudhuri A & Dandona P 2006 Glucose ingestion induces an increase in intranuclear nuclear factor κB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism: Clinical and Experimental 55 1177-1185.
4. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, Chamontin B, Drouet L & Ferrieres J 2003 Soluble CD14 and aortic stiffness in a population-based study. Journal of Hypertension 21 1869-1877.
5. Antal-Szalmas P 2000 Evaluation of CD14 in host defense. European Journal of Clinical Investigation 30 167-179.
6. Bas S, Gauthier BR, Spenato U, Stingelin S & Gabay C 2004 CD14 is an acute-phase protein. Journal of Immunology 172 4470-4479.
7. Bell GW, Large DM & Barclay SC 2000 Oral health care in diabetes mellitus. South African Dental Journal 55 158-165.
8. Dicknson DA, Iles KE, Zhang H, Blank V & Forman HJ 2003 Curcumin alters EpRE and AP-1 binding complexes and elevates glutamate-cysteine ligase gene expression. FASEB Journal 17 473-475.
9. Fogelstrand L, Hulthe J, Hulten LM, Wiklund O & Fagerberg B 2004 Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance. Diabetologia 47 1948-1952.
10. Grossi SG 2001 Treatment of periodontal disease and control of diabetes: an assessment of the evidence and need for future research. Annals of Periodontology 6 138-145.
11. Guha M & Mackman N 2001 LPS induction of gene expression in human monocytes. Cellular Signalling 13 85-94.
12. Haziot A, Rong GW, Silver J & Goyert SM 1993 Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. Journal of Immunology 151 1500-1507.
13. Hisaka H, Kataoka M, Higuchi Y, Matsuura K & Yamamoto S 1999 Close localization of mouse CD14 and CD32/16 in the cell surface of monocytic cell lines. Pathobiology 67 92-98.
14. Kannel WB & McGee DL 1979 Diabetes and cardiovascular disease. The Framingham Study. Journal of the American Medical Association 241 2035-2038.
15. Kol A, Lichtman AH, Finberg RW, Libby P & Kurt-Jones EA 2000 Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. Journal of Immunology 164 13-17.
16. Libby P 1995 Molecular bases of the acute coronary syndromes. Circulation 91 2844-2850.
17. Loppnow H, Stelter F, Schonbeck U, Schluter C, Ernst M, Schutt C & Flad HD 1995 Endotoxin activates human vascular smooth muscle cells despite lack of expresson of CD14 mRNA or endogenous membrane CD14. Infection and Immunity 63 1020-1026.
18. Maldonado A, He L, Game BA, Nareika A, Sanders JJ, London SD, Lopes-Virella MF & Huang Y 2004 Pre-exposure to high glucose augments lipopolysaccharide-stimulated matrix metalloproteinase-1 expression by human U937 histiocytes. Journal of Periodontal Research 39 415-423.
19. Matrisian LM 1992 The matrix-degrading metalloproteinases. BioEssays 14 455-463.
20. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H & Dandona P 2000 Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. Journal of Clinical Endocrinology and Metabolism 85 2970-2973.
21. Nareika A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF & Huang Y 2005 Sodium lactate increases LPS-stimulated MMP and cytokine expression in U937 histiocytes by enhancing AP-1 and NFκB transcriptional activities. American Journal of Physiology. Endocrinology and Metabolism 289 E534-E542.
22. Nareika A, Maldonado A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF & Huang Y 2006 High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin. Journal of Periodontal Research 42 31-38.
23. Nockber WA, Wigand R, Schoeppe W & Scherberich JE 1994 Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clinical and Experimental Immunology 96 15-19.
24. Oesterreicher C, Pfeffel F, Petermann D & Muller C 1995 Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. Journal of Hepatology 23 396-402.
25. Ooi ST, Frazee LA & Gardner WG 2004 Management of asymptomatic bacteriuria in patients with diabetes mellitus. Annals of Pharmacotherapy 38 490-493.
26. Patino, R, Ibarra J, Rodriguez A, Ruiz-Yague M, Pinter E, Fernandez-Cruz A & Figueredo A 2000 Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. American Journal of Cardiology 85 1288-1291.
27. Position paper 1999 Diabetes and periodontal diseases. Journal of Periodontology 70 935-949.
28. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ & Tobias PS 1993 Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. PNAS 90 2744-2748.
29. Pugin J, Heumann ID, Tomasz A, Kravcheno VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS & Ulevitch RJ 1994 CD14 is a pattern recognition receptor. Immunity 1 509-516.
30. Pyorala K, Laakso M & Unsitupa M 1987 Diabetes and atherosclerosis: an epidermiologic view. Diabetes/Metabolism Reviews 3 463-524.
31. Schmitz G & Orso E 2002 CD14 signaling in lipid rafts: new ligands and co-receptors. Current Opinion in Lipidology 13 513-521.
32. Sundstrom C & Nilsson K 1976 Establishment and characterization of a human histiocytic lymphoma cell line (U937). International Journal of Cancer 17 565-577.
33. Takeshita S, Nakatani K, Tsujimoto H, Kawamura Y, Kawase H & Sekine I 2000 Increased levels of circulating soluble CD14 in Kawasaki disease. Clinical and Experimental Immunology 119 376-381.
34. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM & Dimmeler S 2003 Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108 2511-2516.
35. Viriyakosol S & Kirkland TN 1996 The N-terminal half of membrane CD14 is a functional cellular lipopolysaccharide receptor. Infection and Immunity 64 653-656.
36. Vogel SN, Perera PY, Detore GR, Bhat N, Carboni JM, Haziot A & Goyert SM 1998 CD14 dependent and independent signaling pathways in murine macrophages from normal and CD14 'knockout' (CD14KO) mice stimulated with LPS or taxol. Progress in Clinical and Biological Research 397 137-146.
37. Wong PM, Chugn SW & Sultzer BM 2000 Genes, receptors, signals and responses to lipoolysaccharide endotoxin. Scandinavian Journal of Immunology 51 123-127.
38. Wuthrich B, Kagi MK & Joller-Jemelka H 1992 Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis. Archives of Dermatological Research 284 339-342.
39. Yu S, Nakashima N, Xu BH, Matsuda T, Izumihara A, Sunahara N, Nakamura T, Tsukano M & Matsuyama T 1998 Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatology International 17 237-243.